Biosynex SA

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, BIM.PA has a market cap of 13.71B. Regarding current trading prices, ALBIO.PA is priced at $1.27, while BIM.PA trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas BIM.PA's P/E ratio is 31.86. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to BIM.PA's ROE of +0.11%. Regarding short-term risk, ALBIO.PA is more volatile compared to BIM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, ERF.PA has a market cap of 9.91B. Regarding current trading prices, ALBIO.PA is priced at $1.27, while ERF.PA trades at $56.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas ERF.PA's P/E ratio is 26.96. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ERF.PA's ROE of +0.05%. Regarding short-term risk, ALBIO.PA is more volatile compared to ERF.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, LBIRD.PA has a market cap of 264.12M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while LBIRD.PA trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas LBIRD.PA's P/E ratio is 46.15. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to LBIRD.PA's ROE of +0.03%. Regarding short-term risk, ALBIO.PA is less volatile compared to LBIRD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, ALECR.PA has a market cap of 103.91M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while ALECR.PA trades at $20,600.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas ALECR.PA's P/E ratio is 14.33. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ALECR.PA's ROE of +0.13%. Regarding short-term risk, ALBIO.PA is more volatile compared to ALECR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, MDXH.BR has a market cap of 85.63M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while MDXH.BR trades at $3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas MDXH.BR's P/E ratio is -1.58. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to MDXH.BR's ROE of -0.93%. Regarding short-term risk, ALBIO.PA is less volatile compared to MDXH.BR. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, BCART.BR has a market cap of 27.24M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while BCART.BR trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas BCART.BR's P/E ratio is -0.32. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to BCART.BR's ROE of +2.04%. Regarding short-term risk, ALBIO.PA is more volatile compared to BCART.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, ALPRE.PA has a market cap of 13.85M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while ALPRE.PA trades at $3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas ALPRE.PA's P/E ratio is -2.96. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to ALPRE.PA's ROE of +3.12%. Regarding short-term risk, ALBIO.PA is more volatile compared to ALPRE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, EEP.MC has a market cap of 6.26M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while EEP.MC trades at $0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas EEP.MC's P/E ratio is -54.00. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to EEP.MC's ROE of N/A. Regarding short-term risk, ALBIO.PA is less volatile compared to EEP.MC. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, MLAHC.PA has a market cap of 5.41M. Regarding current trading prices, ALBIO.PA is priced at $1.27, while MLAHC.PA trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas MLAHC.PA's P/E ratio is -10.00. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to MLAHC.PA's ROE of N/A. Regarding short-term risk, ALBIO.PA is more volatile compared to MLAHC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for ALBIO.PA.

ALBIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALBIO.PA stands at 23.03M. In comparison, GV.PA has a market cap of 693191.00. Regarding current trading prices, ALBIO.PA is priced at $1.27, while GV.PA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALBIO.PA currently has a P/E ratio of -0.44, whereas GV.PA's P/E ratio is -0.02. In terms of profitability, ALBIO.PA's ROE is -0.38%, compared to GV.PA's ROE of -7.61%. Regarding short-term risk, ALBIO.PA is less volatile compared to GV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for ALBIO.PA.